12,372 trials
Blepharospasm
Primary: Jankovic Rating Scale (JRS) Change From Baseline in the JRS Severity Subscore at Week 6 After Injection (Assessed by a Blinded Independent Rater) — -0.8; 0.2 Points on a…
Pneumococcal Infections
Primary: Percentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 Micrograms (Mcg)/mL, 1 Month After the Infant Series. — 97.0; 97.9…
Depressive Disorder
Primary: Adjusted Mean Change From Baseline in the Hamilton Depression Rating Scale (HAM-D; 17 Items) Total Score at Week 8 — -10.4; -12.8; -12.5 scores on a scale — p=<0.001
Colonoscopy
Primary: Efficacy: Percentage of Patients With Successful Preparations Based on a 4 Point Scale — 89.6; 98.4 percentage of participants — p=0.038
Attention Deficit Hyperactivity Disorder
Primary: Number of Participants With Adverse Events for Long Term Safety and Tolerability — 6; 222 Participants
Bacterial Pneumonia
Primary: Clinical Cure Rate at Test-of-Cure (TOC) in the Modified Intent-to-Treat Efficacy (MITTE) Populations — 244; 233; 34; 58 participants
Diphtheria · Polio · Pertussis
Primary: Percentage of Participant Responding to Pertussis Antigens Post-Dose 3 of Pentacel® or DAPTACEL®, IPOL®, and ActHIB® Vaccinations. — 98; 99; 99; 99 Percentage of…
Bacterial Infections
Primary: Clinical Cure Rate at Test of Cure (TOC) (MITT Population) — 304; 297; 29; 21 participants
Bacterial Pneumonia
Primary: Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at the Test of Cure (TOC) in the Modified Intent to Treat Efficacy (MITTE) Population — 235; 206; 47…
TOBACCO USE CESSATION
Primary: Biochemically Verified 7-day Point Prevalence Abstinence — 89; 58 Participants
Prostate Cancer
Primary: Percentage of Subjects With Suppression of Serum Testosterone (<=50 ng/dL) From Week 4 to Week 48 for Formulation A: Intent-to-treat (ITT) Population for the Primary…
Prostate Cancer
Primary: Time to Objective Disease Progression — 11.7; 10.0 Weeks — p=0.052
Bipolar Disorder
Primary: Time to Recurrence of a Mood Episode (Risperidone LAI Versus Placebo) — 293.39; 270.47 days — p=0.057
Asthma
Primary: The Area Under the Curve From 0 to 12 Hours [AUC](0-12 hr) of the Change From Baseline to the Week 12 Endpoint in Forced Expiratory Volume in One Second (FEV1) — 3.43…
Infections, Streptococcal · Streptococcus Pneumoniae
Primary: Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes — 3.27; 0.03; 3.80; 0.04 µg/mL